Previous 10 | Next 10 |
The FDA approved Lybalvi from Alkermes Plc (ALKS) for the treatment of schizophrenia and bipolar I disorder on the June 1 PDUFA date, notes John McCamant, editor of The Medical Technology Stock Letter — and a participant in the MoneyShow July 13-15 Virtual Expo. Register here for free....
Bausch Health Companies (BHC), Regeneron Pharmaceuticals (REGN), Orthofix Medical (OFIX), and Alkermes (ALKS) are 4 healthcare stocks with strong value and growth qualities. These are a good fit for the current market, as the value component will provide downside protection in the event that ...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Shares of Alkermes plc (NASDAQ:ALKS) traded today at $25.74, eclipsing its 52-week high. This new high was reached on below average trading volume as 160,000 shares traded hands, while the average 30-day volume is approximately 2.3 million shares. Alkermes plc share prices have moved bet...
Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence - Retrospective Study of Veterans Health Administration Data Showed an Association Between VIVITROL Treatment and Reduced Emergency Department Visits and Inpatient Hospital Sta...
With interest rates remaining at near-zero levels, supportive government policies have been driving the growth prospects of several companies. As such, we think it could be wise to bet on Regeneron (REGN), Energy (ET), Teradata (TDC) and Alkermes (ALKS) because they possess solid growth attri...
Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign - CC Sabathia Shares Personal Recovery Journey to Support Education About the Disease - PR Newswire DUBLIN , June 22, 2021 /PRNewswi...
Alkermes plc (NASDAQ:ALKS) traded today at a new 52-week high of $25.35. So far today approximately 160,000 shares have been exchanged, as compared to an average 30-day volume of 2.1 million shares. Alkermes PLC is a fully integrated global biotechnology company that applies its propriet...
The virtual event aims to promote the attainment of pre-launch excellence in strategic cross-functional alignment by optimizing publication strategies and supporting product approvals The three-day event adopts a half-day format to maximize retention and engagement It will feature two...
Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal , not only for Alzheimer's patients, but...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...